Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 367,406 shares of the specialty pharmaceutical company's stock after selling 14,088 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.14% of Collegium Pharmaceutical worth $10,526,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in COLL. JPMorgan Chase & Co. raised its position in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock valued at $29,586,000 after buying an additional 116,327 shares during the period. Principal Financial Group Inc. boosted its holdings in Collegium Pharmaceutical by 3.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after acquiring an additional 64,958 shares during the period. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company's stock valued at $2,686,000 after acquiring an additional 55,572 shares in the last quarter. Finally, Barclays PLC increased its stake in Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after purchasing an additional 45,291 shares during the period.

Remove Ads

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 977 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares in the company, valued at $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is owned by insiders.

Collegium Pharmaceutical Stock Down 0.6 %

Shares of NASDAQ:COLL traded down $0.19 during trading hours on Wednesday, reaching $29.96. The stock had a trading volume of 301,846 shares, compared to its average volume of 418,016. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29. The firm's 50 day moving average is $30.57 and its 200-day moving average is $32.54. The stock has a market capitalization of $943.32 million, a price-to-earnings ratio of 12.91 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. Research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a research note on Friday, January 10th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has an average rating of "Moderate Buy" and a consensus price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.